EL7.AI
StocksMedium•3 August 2026•
1 min read

Autolus Raises 2026 Sales Outlook and Secures $250M Credit Facility

Key Facts

1Autolus reported preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million.
2The company increased its FY 2026 sales guidance to a range of $140 million – $150 million.
3The company secured a five-year credit facility of up to $250 million with Perceptive Advisors.

In a move reflecting the accelerating commercial momentum of cell therapy products, Autolus Therapeutics announced strong preliminary results for the second quarter of 2026. The company reported preliminary AUCATZYL net product revenue of approximately $45 million, leading management to raise its full-year 2026 sales guidance to a range of $140 million to $150 million. According to reports, this performance represents a significant leap in the company's commercial trajectory as it continues to scale its sales operations.

Alongside the guidance upgrade, the company strengthened its financial position by securing a five-year credit facility of up to $250 million with Perceptive Advisors. This strategic financing aims to provide non-dilutive capital to support commercial scaling. Based on the available data, the agreement included issuing warrants to Perceptive to purchase up to 3.5 million American Depositary Receipts (ADSs) at an exercise price of $1.9314 per ADS.

This development arrives as investors digest broader monetary policy following the Federal Reserve's decision to hold interest rates at 3.75% on July 29, 2026. Investors will also monitor upcoming US economic data, such as manufacturing indices, to assess the general operating environment for growth-stage biotechnology firms.